A股異動 | 華蘭生物(002007.SZ)漲4.53% 去年業績增長穩健 毛利率提升明顯
格隆匯4月8日丨華蘭生物(002007.SZ)漲4.53%,報42.95元,暫錄5連陽,最新總市值783億元。公司去年實現營收50.2 億元,同比上升35.8%;歸母淨利潤為16.1億元,同比上升25.7%;扣非歸母淨利潤為14.8億元,同比上升28.8%。淨利潤增長穩健,業績略超預期。報吿期內,公司毛利率為72.7%,同比上升7.75%,公司的毛利率提升,主要源於高毛利四價流感疫苗的銷售大幅增加,疫苗板塊毛利率同比提升4.49個百分點。東北證券最新研報稱,新冠疫情後大眾對疫苗產品認知度提升,流感疫苗使用習慣得到充分培養,華蘭生物作為國內最大四價流感疫苗生產基地,產業化優勢明顯。預計公司2021-2023年歸母淨利潤分別為20.46億元、24.79億元和30.40億元。給予“增持”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.